Chemotherapy and radiation components of neoadjuvant treatment of pancreatic head adenocarcinoma: Impact on perioperative mortality and long-term survival

There is no detectable difference in early outcomes (30-day and 90-day postsurgical mortality) among pancreaticoduodenectomy patients treated with various types of neoadjuvant therapy. Overall survival appears better among patients exposed preoperatively to full dose systemic chemotherapy rather than concurrent chemoradiation only. Further studies with more detailed data sources are needed.